383 SIRT5-catalyzed demalonylation and inactivation of SDHA block the TCA cycle and induce succinate accumulation, promoting tumorigenesis and drug resistance
This can range from weekly or biweekly infusions to monthly sessions depending on your needs
The barrier will still be an investigational new drug application in an FDA designated disease indication (of which for many of these peptide use cases, there isn't one)
Avoid combining with NSAIDs, which may counteract its healing effects
Injection Site Rotation Repeated injections in exactly the same spot can cause localized irritation, small nodules, or scar tissue formation
Ingredients Active Agents: BPC-157 (Pentadecapeptide) 10mg, TB-500 (Thymosin Beta-4 Analog) 10mg, GHK-Cu (Copper Tripeptide-1) 50mg Format: Sterile Lyophilized Powder (requires reconstitution) Ratio: Synergistic Research Blend (Total Concentration: 70mg per vial) Purity: 99% (HPLC Verified for all components)